Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 16 (2000), Issue 1-2, Pages 53-62

Clinical Applications of Phage-Derived sFvs and sFv Fusion Proteins

K. A. Chester, J. Bhatia, G. Boxer, S. P. Cooke, A. A. Flynn, A. Huhalov, A. Mayer, R. B. Pedley, L. Robson, S. K. Sharma, D. I. R. Spencer, and R. H. J. Begent

CRC Targeting and Imaging Group, Department of Oncology, RFUCMS, University College London, Royal Free Campus, London NW3 2PF, UK

Received 12 March 2001; Accepted 12 March 2001

Copyright © 2000 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Single chain Fv antibodies (sFvs) have been produced from filamentous bacteriophage libraries obtained from immunised mice. MFE-23, the most characterised of these sFvs, is reactive with carcinoembryonic antigen (CEA), a glycoprotein that is highly expressed in colorectal adenocarcinomas. MFE-23 has been expressed in bacteria and purified in our laboratory for two clinical trials; a gamma camera imaging trial using 123I-MFE-23 and a radioimmunoguided surgery trial using 125I-MFE-23, where tumour deposits are detected by a hand-held probe during surgery. Both these trials show MFE-23 is safe and effective in localising tumour deposits in patients with cancer. We are now developing fusion proteins which use MFE-23 to deliver a therapeutic moiety; MFE-23::CPG2 targets the enzyme carboxypeptidase G2 (CPG2) for use in the ADEPT (antibody directed enzyme prodrug therapy) system and MFE::TNFα aims to reduce sequestration and increase tumor concentrations of systemically administered TNFα.